-
2024-520200-26-00
4
2026-02-13
Inherited anemias
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-519157-10-00
3
2025-11-24
Systemic Lupus Erythematosus
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-516646-19-00
5
2025-08-15
Type 2 diabetic patients with no prior cardiovascular (CV) events
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2024-513965-38-01
5
2025-06-16
Sjögren's Disease
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-507097-41-01
5
2025-03-20
Patients with limited-stage small cell lung cancer (LS-SCLC)
without
-
2023-505252-21-00
4
2025-02-14
Hyperkalemia
-
2023-507717-94-00
5
2024-12-06
Deep partial and full-thickness burns
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2022-502959-54-00
5
2023-09-26
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-505638-82-00
5
2022-01-12
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2023-509331-83-00
5
2021-07-28
complement 3 glomerulopathy
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer